Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02224560 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults
A Phase 3 study, sponsored by Jazz Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 225
- Enrollment target
NCT02224560 is a Phase 3 study that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 225 participants.
The verdict
NCT02224560, a Phase 3 study, has completed, sponsored by Jazz Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 225 participants
- Enrollment target
Study Summary
The primary objective of this study was to evaluate the efficacy of GWP42003-P as adjunctive treatment in reducing the number of drop seizures when compared with placebo in participants with Lennox-Gastaut syndrome (LGS).
Interventions
- DRUG Placebo control
- DRUG GWP42003-P
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2015-06-08 |
| Est. Completion | 2016-05-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02224560
The ClinicalTrials.gov registry entry for NCT02224560 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 225 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo control is the first listed.
NCT02224560 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02224560 about?
NCT02224560 is a clinical study titled "Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults". The primary objective of this study was to evaluate the efficacy of GWP42003-P as adjunctive treatment in reducing the number of drop seizures when compared with placebo in participants with Lennox-Gastaut syndrome (LGS).
What is the current status of trial NCT02224560?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 225 participants. The study started on 2015-06-08. Estimated completion is 2016-05-19.
What interventions are being tested in trial NCT02224560?
The interventions under investigation include: Placebo control (DRUG), GWP42003-P (DRUG).
Who is sponsoring clinical trial NCT02224560?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.